Showing 2831-2840 of 2985 results for "".
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Celotres Earns CE Mark Approval for Wound Healinghttps://practicaldermatology.com/news/20120504-celotres_earns_ce_mark_approval_for_wound_healing/2459808/European regulators have granted CE Mark approval for Celotres™ hydrogel scaffold from Halscion, Inc. The CE Mark approval was based on the results of a prospective, multi-center, randomized, same-patient controlled, European clinical trial evaluati
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- PhotoMedex Completes Sale of Common Stock for $40 Millionhttps://practicaldermatology.com/news/20120430-photomedex_completes_sale_of_common_stock_for_40_million/2459812/PhotoMedex, Inc. (NasdaqGS: PHMD) expects gross proceeds of $40 million, before deducting underwriting discounts, commissions and other offering expenses, from recent sale of shares of common stock. The company closed concurrent registered offerin